U.S. markets close in 2 hours 39 minutes

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
286.98-3.10 (-1.07%)
As of 01:20PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close290.08
Bid286.55 x 800
Ask287.13 x 2200
Day's Range285.08 - 289.99
52 Week Range187.16 - 311.88
Avg. Volume1,228,142
Market Cap41.326B
Beta (5Y Monthly)0.21
PE Ratio (TTM)14.76
EPS (TTM)19.45
Earnings DateFeb 15, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est322.30
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-18% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for BIIB

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Biogen Inc.
    Analyst Report: Biogen Inc.Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.
    Fair Value
    Economic Moat
    24 days agoMorningstar
View more
  • Insider Monkey

    15 Biggest Neuroscience Companies in the World

    In this article, we will discuss the 15 Biggest Neuroscience Companies in the World. You can skip our industry overview and go directly to the 5 Biggest Neuroscience Companies in the World. As the name suggests, neuroscience concerns itself with the development, structure, and functions of the nervous system, intending to enhance neurological health. According […]

  • Reuters

    UPDATE 1-Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen

    Japanese drugmaker Eisai Co Ltd and U.S. biotech firm Biogen Inc said in a joint statement that the Japanese Ministry of Health, Labour and Welfare has granted priority review status to their Alzheimer's disease treatment. In their Jan. 29 statement, the companies said priority review in Japan is granted to new medicines recognised as having high medical utility for serious diseases. Once the priority status has been granted, the target total review period is shortened, they said.

  • GlobeNewswire

    Lecanemab Receives Priority Review Status in Japan

    TOKYO and CAMBRIDGE, Mass., Jan. 29, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that an application for manufacturing and marketing approval for lecanemab (generic name, U.S. brand name: LEQEMBI™), an anti-amyloid-β (Aβ) protofibril* antibody, in Japan has been designated for Priority Review by the Japanese Minis